MediWound Ltd.
MDWDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States,. The company carries a $183.5M market cap, placing it firmly in the micro-cap category. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Market Cap
$183.5M
Beta
0.14
P/E (TTM)
—
P/E (Fwd)
-6.43
EPS (TTM)
$-2.21
EPS (Fwd)
$-2.22
ROE
-71.8%
ROA
-23.5%
Cash
$44.6M
Total Debt
$8.1M
Free CF
-$18.4M
52W Change
-30.3%
Annual Financials
Cash vs Debt
Where MDWD stands vs its 150-day and 200-day moving averages
As of the June 22, 2026 close, MDWD finished 16.73% below its 150-day moving average ($17.10) and 17.74% below its 200-day moving average ($17.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDWD overbought or oversold?
At the June 22, 2026 close, MDWD's RSI(14) was 48.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MediWound Ltd. holds $44.6M in cash against $8.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$18.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -71.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $26.5M (2022) to $17.0M (2025), a 36% decline worth watching.
The relatively low beta of 0.14 suggests MDWD is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for MediWound Ltd. and its sector.